腫瘤學市場規模、佔有率及成長分析（按治療類型、藥物類別、給藥途徑、癌症類型、最終用戶、分銷管道和地區）－2025-2032 年產業預測

2023 年癌症治療市場規模價值 2,106.9 億美元，預計將從 2024 年的 2,315.5 億美元成長到 2032 年的 4,927.5 億美元，預測期內（2025-2032 年）的複合年成長率為 9.9%。

由於全球癌症發病率不斷上升，癌症治療行業預計將經歷顯著成長。對腫瘤學研究的投入不斷增加以及對先進治療方案的需求不斷成長，為該領域的公司創造了良好的機會。此外，針對各種癌症的基因治療和個人化醫療的日益普及也推動了這個市場的發展。此外，聯合治療的興起和政府對腫瘤學研究的津貼增加預計將在未來幾年推動銷售成長。然而，在這種不斷變化的情況下，抗藥性、癌症異質性以及治療的潛在副作用等挑戰仍然是醫療保健提供者關注的重大問題。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管格局

癌症治療市場規模（按治療類型和複合年成長率） (2025-2032)

• 市場概覽
• 化療
• 免疫療法
• 標靶治療
• 荷爾蒙療法
• 放射治療
• 幹細胞移植
• 基因治療
• 其他新型治療方法

癌症治療市場規模（按藥物類別和複合年成長率） (2025-2032)

• 市場概覽
• 烷化劑
• 抗代謝物
• 抗腫瘤抗生素
• 拓樸異構酶抑制劑
• 有絲分裂抑制劑
• 荷爾蒙療法
• 免疫查核點抑制劑
• 其他

癌症治療市場規模（按給藥途徑和複合年成長率） (2025-2032)

• 市場概覽
• 口服
• 靜脈
• 皮下
• 肌肉注射
• 局部的
• 其他

癌症治療市場規模（按癌症類型和複合年成長率） (2025-2032)

• 市場概覽
• 肺癌
• 乳癌
• 攝護腺癌
• 大腸直腸癌
• 皮膚癌
• 血癌（白血病、淋巴瘤等）
• 消化道癌
• 婦科癌症
• 呼吸道/肺癌
• 其他類型的癌症

癌症治療市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 醫院
• 專科診所
• 癌症及放射治療中心

癌症治療市場規模（按分銷管道和複合年成長率） (2025-2032)

• 市場概覽
• 醫院藥房
• 零售藥局
• 網路藥局

癌症治療市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Bristol-Myers Squibb（USA）
• Merck & Co.（USA）
• Roche（Switzerland）
• Pfizer（USA）
• Novartis（Switzerland）
• Johnson & Johnson（USA）
• AstraZeneca（UK）
• GlaxoSmithKline（UK）
• Amgen（USA）
• AbbVie（USA）
• Sanofi（France）
• Bayer（Germany）
• Eli Lilly（USA）
• Takeda Pharmaceutical（Japan）
• Astellas Pharma（Japan）
• Gilead Sciences（USA）
• Celgene（USA）
• Daiichi Sankyo（Japan）
• Biogen（USA）
• Dr. Reddy's Laboratories（India）

結論和建議

Cancer Therapeutics Market size was valued at USD 210.69 billion in 2023 and is poised to grow from USD 231.55 billion in 2024 to USD 492.75 billion by 2032, growing at a CAGR of 9.9% during the forecast period (2025-2032).

The cancer therapeutics industry is poised for significant growth as the global prevalence of cancer continues to rise. Increased investments in oncology research and an escalating demand for advanced treatment options are creating promising opportunities for companies in this sector. The market is further enhanced by the escalating adoption of gene therapies and personalized medicine tailored for various cancer types. Additionally, the rise of combination therapies and heightened government funding for oncology research are expected to drive sales in the coming years. However, challenges such as drug resistance, the heterogeneity of cancer, and potential adverse effects of treatments remain critical concerns for providers in this evolving landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Therapeutics Market Segments Analysis

Global Cancer Therapeutics Market is segmented by Therapy Type, Drug Class, Route of Administration, Cancer Type, End User, Distribution Channel and region. Based on Therapy Type, the market is segmented into Chemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy, Radiation Therapy, Stem Cell Transplant, Gene Therapy and Other Emerging Therapies. Based on Drug Class, the market is segmented into Alkylating Agents, Antimetabolites, Antitumor Antibiotics, Topoisomerase Inhibitors, Mitotic Inhibitors, Hormone Therapies, Immune Checkpoint Inhibitors and Others. Based on Route of Administration, the market is segmented into Oral, Intravenous, Subcutaneous, Intramuscular, Topical and Others. Based on Cancer Type, the market is segmented into Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Skin Cancer, Blood Cancer (Leukemia, Lymphoma, etc.), Gastrointestinal Cancer, Gynecologic Cancer, Respiratory/Lung Cancer and Other Cancer Types. Based on End User, the market is segmented into Hospitals, Specialty Clinics and Cancer and Radiation Therapy Centers. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cancer Therapeutics Market

The rise in cancer cases globally can be largely attributed to poor lifestyle choices and the increasing prevalence of unhealthy habits among individuals. This alarming trend has contributed to a substantial increase in the number of individuals diagnosed with cancer, thereby driving the demand for cancer therapeutics. As more people require effective treatments to combat this disease, the cancer therapeutics market is experiencing notable growth. The urgent need for innovative therapies to address the escalating cancer burden is highlighting the importance of investment and research in this market, further fueling its expansion in response to the growing health crisis.

Restraints in the Cancer Therapeutics Market

The rapid evolution of cancer cells and tumors has led to increasing resistance to various treatment modalities, significantly impacting the sales of cancer therapeutics. This resistance not only hampers the effectiveness of existing drugs but also poses a considerable challenge for the entire cancer therapeutics market, ultimately hindering its growth. As therapies become less effective against resistant tumors, the demand for innovative treatments rises, yet the slow pace of drug development and approval can exacerbate market stagnation. Consequently, the challenges posed by evolving cancer biology and drug resistance serve as a significant restraint on the progress of the cancer therapeutics market.

Market Trends of the Cancer Therapeutics Market

The Cancer Therapeutics market is witnessing a significant trend towards the integration of artificial intelligence (AI) in drug discovery and development processes. Companies are increasingly leveraging AI technologies to streamline research initiatives, identify novel drug targets, and enhance the efficacy of existing treatments. This trend not only accelerates innovation but also reduces time-to-market for new therapies. Additionally, AI is poised to play a broader role across various facets of the cancer therapeutics landscape, including personalized medicine and patient management, thereby driving efficiency and improving clinical outcomes. As this trend matures, it is expected to reshape the competitive dynamics of the market significantly.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape

Global Cancer Therapeutics Market Size by Therapy Type & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Hormonal Therapy
• Radiation Therapy
• Stem Cell Transplant
• Gene Therapy
• Other Emerging Therapies

Global Cancer Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Alkylating Agents
• Antimetabolites
• Antitumor Antibiotics
• Topoisomerase Inhibitors
• Mitotic Inhibitors
• Hormone Therapies
• Immune Checkpoint Inhibitors
• Others

Global Cancer Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Topical
• Others

Global Cancer Therapeutics Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Skin Cancer
• Blood Cancer (Leukemia, Lymphoma, etc.)
• Gastrointestinal Cancer
• Gynecologic Cancer
• Respiratory/Lung Cancer
• Other Cancer Types

Global Cancer Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Cancer and Radiation Therapy Centers

Global Cancer Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Cancer Therapeutics Market Size & CAGR (2025-2032)

• North America (Therapy Type, Drug Class, Route of Administration, Cancer Type, End User, Distribution Channel)
  • US
  • Canada
• Europe (Therapy Type, Drug Class, Route of Administration, Cancer Type, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Drug Class, Route of Administration, Cancer Type, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Drug Class, Route of Administration, Cancer Type, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Drug Class, Route of Administration, Cancer Type, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations